Rating Change
Citigroup analysts reiterated a Neutral rating on Moderna, Inc. (NASDAQ:MRNA) on August 03, 2026.
reiterateNASDAQ:MRNA
Citigroup Reiterates Neutral Rating on Moderna, Inc. (MRNA)
Rating Change Citigroup analysts reiterated a Neutral rating on Moderna, Inc. (NASDAQ:MRNA) on August 03, 2026. Market Context Moderna, Inc.
Market Context
Moderna, Inc. operates in the Healthcare sector. The stock currently trades at $55.14 with a market capitalization of $11.6B. The stock has gained 120.0% over the past 52 weeks.
Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Moderna, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Moderna, Inc.
Among the 10 most recent ratings: 1 Buy, 7 Hold, 2 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 03, 2026 | Citigroup | Neutral | N/A |
| Jul 21, 2026 | Goldman Sachs | Neutral | N/A |
| Jul 08, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Jul 07, 2026 | B of A Securities | Underperform | N/A |
| Jul 07, 2026 | RBC Capital | Sector Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View MRNA Stock Page
Frequently Asked Questions
What does a Neutral rating mean for MRNA?
A Neutral rating from Citigroup reflects the analyst's outlook on Moderna, Inc. (NASDAQ:MRNA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRNA forecast page.
